Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point<sup>18</sup>F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Cho, Steve Y.; Lipson, Evan J.; Im, Hyung Jun; Rowe, Steven P.; Gonzalez, E. M.; Blackford, Amanda L.; Chirindel, Alin; Pardoll, Drew M.; Topalian, Suzanne L.; Wahl, Richard L.

doi:10.2967/jnumed.116.188839

Cited by 217 publications

(208 citation statements)

References 32 publications

Supporting

Mentioning

190

Contrasting

Unclassified

Order By: Relevance

“…Two studies in patients with melanoma demonstrated the inability of FDG‐PET/CT to differentiate between patients who had pseudoprogression because of inflammatory infiltrate and those who had actual PD . Cho et al evaluated the ability of FDG‐PET/CT in conjunction with other imaging modalities to predict early response to therapy in patients with advanced melanoma who receive treatment with several checkpoint inhibitors . At each post‐treatment time point, response was assessed based on RECIST 1.1, irRC, Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST 1.0), and European Organization for Research and Treatment of Cancer criteria.…”

Section: Implementation Of Response Criteria In Clinical Trialsmentioning

confidence: 99%

“…15,16 Cho et al evaluated the ability of FDG-PET/CT in conjunction with other imaging modalities to predict early response to therapy in patients with advanced melanoma who receive treatment with several checkpoint inhibitors. 17 At each post-treatment time point, response was assessed based on RECIST 1.1, irRC, Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST 1.0), and European Organization for Research and Treatment of Cancer criteria. Those authors developed criteria comprised of anatomic and functional information that predicted eventual response with 100% sensitivity, 93% specificity, and 95% accuracy.…”

Section: Immunotherapy and The Role Of Imaging/carter Et Almentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy and the role of imaging

Carter

Bhosale

Yang

2018

Cancer

View full text Add to dashboard Cite

Significant advances in the genetic and molecular characterization of cancer have led to the development of effective immunotherapies. These therapeutics help the host immune system recognize cancer as foreign, promote the immune system, and relieve the inhibition that allows growth and spread of tumors. Experience with various immunotherapies, particularly the immunomodulatory monoclonal antibody ipilimumab, has demonstrated that unique patterns of response may be encountered that cannot be adequately captured by traditional response criteria, such as the World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), which have been used primarily with cytotoxic chemotherapies. In response to these observations, several novel response criteria have been developed to evaluate patients who receive immunotherapy, including immune-related response criteria (irRC), immune-related RECIST (irRECIST), and immune RECIST (iRECIST). These criteria are typically used in conjunction with RECIST version 1.1 in the clinical trial setting, because approval of new therapeutics by the US Food and Drug Administration relies on the responses derived from RECIST version 1.1. Finally, a wide variety of immune-related adverse events may affect patients who receive immunotherapy, many of which can be identified on imaging studies such as computed tomography, magnetic resonance imaging, and 2-deoxy-2-(fluorine-18)fluoro-D-glucose-positron emission tomography/computed tomography. In this review, the authors present the role of imaging in the evaluation of patients treated with immunotherapy, including the background and application of irRC, irRECIST, and iRECIST; the imaging of immune-related adverse events; and future directions in advanced imaging of immunotherapy. Cancer 2018;124:2906-22. © 2018 American Cancer Society.

show abstract

Section: Implementation Of Response Criteria In Clinical Trialsmentioning

confidence: 99%

Section: Immunotherapy and The Role Of Imaging/carter Et Almentioning

confidence: 99%

Immunotherapy and the role of imaging

Carter

Bhosale

Yang

2018

Cancer

View full text Add to dashboard Cite

show abstract

“…Outcomes from these studies indicated that 18 F‐FDG PET/CT scan can provide complementary information to classic anatomic imaging including CT and MR imaging, however, larger cohorts are warranted to validate these findings from studies with small sample size. Of note, it is essential for radiologists to realize that increased 18 F‐FDG uptake is not specific for neoplasms regardless of its high sensitivity, because other pathological processes, including inflammatory reaction, can also show elevated glucose metabolism.…”

Section: Imaging Biomarkers For Immune Checkpoint Therapymentioning

confidence: 99%

“…Of note, it is essential for radiologists to realize that increased 18 F‐FDG uptake is not specific for neoplasms regardless of its high sensitivity, because other pathological processes, including inflammatory reaction, can also show elevated glucose metabolism. In this setting, it is a great challenge for readers to distinguish tumor progression and metastases from inflammation on PET scans . Future efforts are warranted to solve this dilemma in 18 F‐FDG PET/CT.…”

Section: Imaging Biomarkers For Immune Checkpoint Therapymentioning

confidence: 99%

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction

2019

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) represents a promising approach in cancer therapy. Owing to the peculiar biologic mechanisms of anticancer activity, checkpoint blockers are accompanied with distinctive response patterns and toxicity profiles. Medical imaging is the cornerstone for response assessment to immunotherapy and plays a critical role in monitoring of immune‐related adverse events (irAEs). Imaging‐based biomarkers have shown tremendous potential for the prediction of therapeutic efficacies and clinical outcomes in patients treated with checkpoint inhibitors. In this article, the landscape of current response assessment systems for immunotherapy was reviewed with a special focus on the latest advances in the assessment of responses to ICB. Emerging imaging biomarkers were discussed along with the challenges regarding their clinical transformation. In addition, the biological mechanisms and clinical applications of ICB and irAEs were also within the scope of this review.

show abstract

“…42,43 However, since [ 18 F]FDG accumulates in the immune activated region, it may not be easy to predict the therapeutic effect in some patients. 44 In some cases, a combination of several imaging agents might be effective for prediction and monitoring the therapies.…”

Section: Biomedical Analysis By Nuclear Imagingmentioning

confidence: 99%

In Vivo Molecular Imaging for Biomedical Analysis and Therapies

Ogawa

Takakura

2018

ANAL. SCI.

View full text Add to dashboard Cite

In vivo molecular imaging is a powerful tool to analyze the human body. Precision medicine is receiving high attention these days, and molecular imaging plays an important role as companion diagnostics in precision medicine. Nuclear imaging with PET or SPECT and optical imaging technologies are used for in vivo molecular imaging. Nuclear imaging is superior for quantitative imaging, and whole-body analysis is possible even for humans. Optical imaging is superior due to its ease of use, and highly targeted specific imaging is possible with activatable agents. However, with optical imaging using fluorescence, it is difficult to obtain a signal from deep tissue and quantitation is difficult due to the attenuation and scattering of the fluorescent signal. Recently, to overcome these issues, optoacoustic imaging has been used in in vivo imaging. In this article, we review in vivo molecular imaging with nuclear and optical imaging and discuss their utility for precision medicine.

show abstract

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Cited by 217 publications

References 32 publications

Immunotherapy and the role of imaging

Immunotherapy and the role of imaging

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction

In Vivo Molecular Imaging for Biomedical Analysis and Therapies

Contact Info

Product

Resources

About

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point18F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Cited by 217 publications

References 32 publications

Immunotherapy and the role of imaging

Immunotherapy and the role of imaging

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction

In Vivo Molecular Imaging for Biomedical Analysis and Therapies

Contact Info

Product

Resources

About

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma